We have three primary areas of business:  Pharmaceuticals, Vaccines and Consumer Healthcare. Our objective is to deliver sustainable growth across this broad portfolio. In 2012, group turnover was £26.4 billion.

Pharmaceuticals

Our Pharmaceuticals business develops and makes available medicines to treat a broad range of serious and chronic diseases. Our portfolio is made up of established brands and newer innovative patent-protected medicines.

Vaccines

Our Vaccines business is one of the largest in the world, producing paediatric and adult vaccines against a range of infectious diseases. In 2012, we distributed nearly 900 million doses to 170 countries, of which over 80% were supplied to developing countries.

Consumer Healthcare

We develop and market a range of consumer health products based on scientific innovation. We have brands in four main categories: Total wellness, Oral care, Nutrition and Skin health.

Research & Development

Our business is sustained through investment in R&D. In 2012 we spent £3.5 billion before non-core items - £4.0 billion in total - in our search to develop new medicines, vaccines and innovative consumer products.

During the year we saw significant delivery from our late-stage pipeline, with six key medicines filed with regulators.

We have dedicated research programmes for diseases that affect the developing world. We are one of the few healthcare companies researching both new vaccines and new medicines for all three of the World Health Organization’s priority diseases: HIV/AIDS, malaria and tuberculosis.